3. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
4. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993;306:481-483.
5. Finn WF. Recovery from acute renal failure. In: Lazarus JM, Brenner BM, eds. Acute renal failure. 3d ed. New York: Churchill Livingstone, 1993:553-596.
6. Better OS, Stein JH. Current consepts: Early management of shock and prophylaxis of Acute Renal Failure in Traumatic Rhabdomyolysis. New England J of Med 1990;322 (12):825-829.
7. Brezis M, Rosen S, Epstein FH. Acute renal failure. In Brenner BM, Rector FC (eds)., The Kidney, 4 th Ed, WB Saunders Company: Philadelphia, 1991:993-1061.
8. Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. N Engl J Med 1998;339:888-899.
9. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325: 393-397.
10. Humes D. Aminoglycoside nephrotoxicity. Kidney Int 1988;33:900-911.
11. Rizk NW, Kalassian KG, Gilligan T, Druzin MI, Daniel DL. Obstetric complications in pulmonary and critical care medicine. Chest 1996;110:791-809.
12. Zagler A, Azadpour M, Mercado C, Hennekens CH.N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140-145.
13. Ferreira SH. Angiotensin converting enzyme: history and relevance. Semin Perinatol. 2000;24(1):7-10.
14. Martinez-Maldonado M, Kumjian DA. Acute renal failure due to urinary tract obstruction. Med Clin North Am 1990;74:919-32.
15. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
17. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
18. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic- contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
19. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289;553-558.
20. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS). Clinical Trials Group. Lancet 2000;356:2139-2143.
Akut böbrek yetmezliği
Year 2010,
Volume: 2 Issue: 1, 46 - 52, 01.04.2010
Akut böbrek yetersizliði (ABY), böbrek fonksiyonlarýnýn kýsa bir süre (saatler ve günler) içinde ani bozulmasý sonucu glomerüler filtrasyon hýzýnda azalma, üre ve kreatininin kanda birikimi, sývý elektrolit bozukluðu, idrar miktarýnda azalma ile karakterizedir. Bazý olgularda idrar miktarýnda azalma olmadan ABY geliºebilir (nonoligürik ABY). Normal böbrek fonksiyonu için saðlam nefronun perfüzyonu, yeterli glomerüler ultrafiltrasyon, yeterli tubulüs fonksiyonu ve idrar yollarýnýn açýk olmasý gereklidir. Bu aºamalardan birinde aksama olduðunda ABY ortaya çýkabilir. Sonuç olarak oligüri ve kýsa sürede ortaya çýkan azotemi ABY'nin özellikleridir
3. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
4. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993;306:481-483.
5. Finn WF. Recovery from acute renal failure. In: Lazarus JM, Brenner BM, eds. Acute renal failure. 3d ed. New York: Churchill Livingstone, 1993:553-596.
6. Better OS, Stein JH. Current consepts: Early management of shock and prophylaxis of Acute Renal Failure in Traumatic Rhabdomyolysis. New England J of Med 1990;322 (12):825-829.
7. Brezis M, Rosen S, Epstein FH. Acute renal failure. In Brenner BM, Rector FC (eds)., The Kidney, 4 th Ed, WB Saunders Company: Philadelphia, 1991:993-1061.
8. Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. N Engl J Med 1998;339:888-899.
9. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325: 393-397.
10. Humes D. Aminoglycoside nephrotoxicity. Kidney Int 1988;33:900-911.
11. Rizk NW, Kalassian KG, Gilligan T, Druzin MI, Daniel DL. Obstetric complications in pulmonary and critical care medicine. Chest 1996;110:791-809.
12. Zagler A, Azadpour M, Mercado C, Hennekens CH.N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140-145.
13. Ferreira SH. Angiotensin converting enzyme: history and relevance. Semin Perinatol. 2000;24(1):7-10.
14. Martinez-Maldonado M, Kumjian DA. Acute renal failure due to urinary tract obstruction. Med Clin North Am 1990;74:919-32.
15. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
17. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
18. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic- contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
19. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289;553-558.
20. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS). Clinical Trials Group. Lancet 2000;356:2139-2143.